Details
Stereochemistry | RACEMIC |
Molecular Formula | C22H28ClO6.Na |
Molecular Weight | 446.897 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].O[C@@H](COC1=CC=CC(Cl)=C1)\C=C\[C@H]2[C@H](O)C[C@H](O)[C@@H]2C\C=C/CCCC([O-])=O
InChI
InChIKey=IFEJLMHZNQJGQU-KXXGZHCCSA-M
InChI=1S/C22H29ClO6.Na/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28;/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28);/q;+1/p-1/b3-1-,11-10+;/t16-,18-,19-,20+,21-;/m1./s1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H28ClO6 |
Molecular Weight | 423.907 |
Charge | -1 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
Cloprostenol is a synthetic prostaglandin analogue structurally related to Prostaglandin F2α (PGF2α), for use in cattle and horses. As a potent luteolytic agent it causes functional and morphological regression of the corpus luteum (luteolysis) in cattle and horses followed by return to oestrus and normal ovulation.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12213132
Curator's Comment: Cloprostenol doesn`t cross the blood-brain barrier in pigs
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P43088 Gene ID: 5737.0 Gene Symbol: PTGFR Target Organism: Homo sapiens (Human) |
10.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | GONABREED Approved UseGONABREED, for estrous synchrony in lactating dairy cows and beef cows. GONABREED (Abbreviated New Animal Application 200-541) is a sterile injectable solution of gonadorelin acetate, and when used with cloprostenol sodium as part of a synchronization regimen, the drug can be used to synchronize estrous cycles to allow for fixed time artificial insemination in lactating dairy cows and beef cows. Launch Date2013 |
|||
Primary | Cloprochem Approved UseCattle:
- Functional ovarian disorders such as anoestrus due to persistent corpus luteum, suboestrus, luteal or follicular cysts.
- Synchronisation of oestrus.
- Induction of parturition or abortion (associated increased incidence of retained foetal membranes, retentio secundinarum). Postpuerperium disorders of the uterus (e.g. pyometra, endometritis).
Mares:
- Induction of luteolysis following early foetal death and resorption
- Termination of persistent dioestrus
- Termination of pseudopregnancy
- Treatment of lactation anoestrus
- Induction of oestrus cycling in mares
- Aid to stud management |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacology of [3H]prostaglandin E1/[3H]prostaglandin E2 and [3H]prostaglandin F2alpha binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data. | 1998 Aug |
|
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. | 2000 Jan 17 |
|
Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. | 2002 Apr |
|
Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) expression during induced luteolysis in the bovine corpus luteum. | 2004 Apr |
|
Acquisition of luteolytic capacity involves differential regulation by prostaglandin F2alpha of genes involved in progesterone biosynthesis in the porcine corpus luteum. | 2005 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15971828
2 ml per single or repeated dose in cattle and horses
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24268486
In the cultured bovine luteal cells, [Ca2+]i increased after treatment with 1 ug/mL of Cloprostenol 15 s after treatment with 140% of the control.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:40 GMT 2023
by
admin
on
Fri Dec 15 15:25:40 GMT 2023
|
Record UNII |
886SAV9675
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78568
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
||
|
CFR |
21 CFR 522.460
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
259-439-3
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
886SAV9675
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
886SAV9675
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
DBSALT001672
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
m3658
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76897
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
DTXSID1046500
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
204179
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
55028-72-3
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
100000166274
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
SUB180342
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL2220404
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
1140666
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY | |||
|
17756794
Created by
admin on Fri Dec 15 15:25:40 GMT 2023 , Edited by admin on Fri Dec 15 15:25:40 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |